MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Current Deferred Revenue: ₺0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IST:MEDTR MEDITERA TIBBI MALZEME SANAYI VE TICARET AS IST:MEDTR
86 GF Score
Price ₺25.28
GF Value ₺39.62
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is MEDITERA TIBBI MALZEMENAYI VE TICARET AS Current Deferred Revenue?

MEDITERA TIBBI MALZEMENAYI VE TICARET AS IST:MEDTR -2.09% 86 Current Deferred Revenue is ₺0 Mil as of Jun. 2026. GuruFocus rates IST:MEDTR with a GF Score™ of 86/100 and a GF Value™ of ₺39.62 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current deferred revenue for the quarter that ended in Jun. 2026 was ₺0 Mil.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Current Deferred Revenue Related Terms

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Current Deferred Revenue Chart

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IST:MEDTR
86GF Score
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS IST:MEDTR
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₺0 Mil mean?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a Current Deferred Revenue of ₺0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Current Deferred Revenue too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Current Deferred Revenue is ₺0 Mil. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Current Deferred Revenue compare to ABT and SYK?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Current Deferred Revenue of ₺0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Current Deferred Revenue is ₺0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺39.62, compared to a current price of ₺25.28 — trading 36.2% below its estimated fair value. The current Current Deferred Revenue is ₺0 Mil. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current Current Deferred Revenue is ₺0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?

Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued. The current stock price of ₺25.28 is trading 36.2% below its estimated GF Value™ of ₺39.62. GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.

Key valuation signals for IST:MEDTR:

  • Current Deferred Revenue: ₺0 Mil
  • GF Value™: ₺39.62 vs. price of ₺25.28 (36.2% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MEDITERA TIBBI MALZEMENAYI VE TICARET AS Business Description

Address Sokak No: 29 Tire Organize Sanayi, Ibni Melek OSB Mahallesi, TOSBI Yol 4, Bolgesi Tire, Izmir, TUR, 35900
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
86GF Score

Get the complete analysis for IST:MEDTR

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺25.28
Price
₺39.62
GF Value